These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 7550391)

  • 1. Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid.
    Atzpodien J; Kirchner H; Duensing S; Lopez Hänninen E; Franzke A; Buer J; Probst M; Anton P; Poliwoda H
    World J Urol; 1995; 13(3):174-7. PubMed ID: 7550391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
    Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
    Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].
    Atzpodien J; Kirchner H; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():38-43. PubMed ID: 8692118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients.
    Lopez Hänninen E; Kirchner H; Atzpodien J
    J Urol; 1996 Jan; 155(1):19-25. PubMed ID: 7490829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consolidation biochemotherapy for patients with advanced nonsmall cell lung carcinoma responding to induction PVM (cisplatin, vinblastine, mitomycin-C) regimen. A phase II study.
    Tummarello D; Graziano F; Isidori P; Santo A; Cetto G; Fedeli A; Rossi G; Cellerino R
    Cancer; 1996 Jun; 77(11):2251-7. PubMed ID: 8635092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Bodenstein H; Pfreundschuh M; Rebmann U; Metzner B; Illiger HJ; Jakse G; Niesel T
    J Clin Oncol; 1995 Feb; 13(2):497-501. PubMed ID: 7844611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma.
    Olencki T; Peereboom D; Wood L; Budd GT; Novick A; Finke J; McLain D; Elson P; Bukowski RM
    J Cancer Res Clin Oncol; 2001 May; 127(5):319-24. PubMed ID: 11355147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10.
    Soori G; Dillman RO; Wiemann MC; Stark JJ; Tai F; DePriest CB; Church CK; Schulof R
    Cancer Biother Radiopharm; 2002 Apr; 17(2):165-73. PubMed ID: 12030110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma. Results of two phase II clinical trials.
    Bacoyiannis C; Dimopoulos MA; Kalofonos HP; Nicolaides C; Aravantinos G; Bafaloukos D; Samelis G; Onyenadum A; Kiamouris Ch; Skarlos D; Pavlidis N; Triantafillidis A; Kosmidis P;
    Oncology; 2002; 63(2):130-8. PubMed ID: 12239447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
    Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer.
    Pectasides D; Varthalitis J; Kostopoulou M; Mylonakis A; Triantaphyllis D; Papadopoulou M; Dimitriadis M; Athanassiou A
    Oncology; 1998; 55(1):10-5. PubMed ID: 9428369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer.
    Atzpodien J; Kirchner H; Hänninen EL; Deckert M; Fenner M; Poliwoda H
    Eur J Cancer; 1993; 29A Suppl 5():S6-8. PubMed ID: 8260264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. alpha-Interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patients.
    Atzpodien J; Poliwoda H; Kirchner H
    Semin Oncol; 1991 Oct; 18(5 Suppl 7):108-12. PubMed ID: 1948123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic and serologic toxicity of systemic interleukin-2 and/or interferon-alpha. Evidence of a risk-benefit advantage of subcutaneous therapy.
    Schomburg A; Kirchner H; Lopez-Hänninen E; Menzel T; Rudolph P; Körfer A; Fenner M; Poliwoda H; Atzpodien J
    Am J Clin Oncol; 1994 Jun; 17(3):199-209. PubMed ID: 7910716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunochemotherapy of metastatic renal cell carcinoma with interleukin 2, interferon-alpha and 5-fluorouracil].
    Hofmockel G; Theiss M; Gruss A; Langer W; Frohmüller H
    Urologe A; 1997 Jan; 36(1):45-9. PubMed ID: 9123681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experience.
    Kirchner H; Körfer A; Palmer PA; Evers P; De Riese W; Knüver-Hopf J; Hadam M; Goldman U; Franks CR; Poliwoda H
    Mol Biother; 1990 Sep; 2(3):145-54. PubMed ID: 2222898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.
    McDermott DF; Mier JW; Lawrence DP; van den Brink MR; Clancy MA; Rubin KM; Atkins MB
    Clin Cancer Res; 2000 Jun; 6(6):2201-8. PubMed ID: 10873069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of metastatic renal cell cancer patients with recombinant subcutaneous human interleukin-2 and interferon-alpha.
    Atzpodien J; Körfer A; Palmer PA; Franks CR; Poliwoda H; Kirchner H
    Ann Oncol; 1990 Sep; 1(5):377-8. PubMed ID: 2261378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-alpha/5-fluorouracil: a novel outpatient chemo/immunotherapy for progressive metastatic renal cell carcinoma.
    Lopez Hanninen E; Poliwoda H; Atzpodien J
    Cancer Biother; 1995; 10(1):21-4. PubMed ID: 7780483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.